According to a report by Intel Market Research, the global Cancer Respiratory Biopsy Market was valued at USD 410 million in 2025 and is estimated to reach USD 480 million in 2026, before growing to USD 1.70 billion by 2034, representing a 17.1% CAGR during 2026–2034. The market covers emerging non-invasive diagnostic approaches that analyze exhaled breath and other respiratory samples for cancer-associated volatile organic compounds (VOCs), volatile reporter molecules and related biomarkers.
Explore the full report: https://www.intelmarketresearch.com/cancer-respiratory-biopsy-market-3188
Why Is Demand Increasing?
- Growing lung-cancer burden: IARC estimated almost 2.5 million new lung-cancer cases worldwide in 2022, creating substantial demand for easier and more accessible early-detection and screening approaches.
- Need for complementary diagnostic tools: Low-dose CT has established evidence for mortality reduction, while respiratory biopsy offers a potential non-invasive approach for screening support, triaging indeterminate imaging findings and repeated longitudinal testing.
- Advances in breath-analysis technology: Standardized breath collection, analytical chemistry, sensor arrays, exogenous VOC probes and algorithmic pattern recognition are moving respiratory biopsy from exploratory biomarker research toward more reproducible diagnostic workflows.
Clinical & Diagnostic Technology Watch
The cancer respiratory biopsy industry is moving toward integrated diagnostic platforms that combine standardized sample collection, analytical measurement and clinical interpretation. Mass spectrometry and gas chromatography-mass spectrometry remain important for VOC identification, validation and reference-library development, while compact sensor arrays offer a potential route toward faster and more decentralized testing. Exogenous VOC probe approaches are also creating a differentiated pathway by generating defined breath-detectable reporters after interaction with disease-associated biology.
Clinical validation remains central to commercialization. Owlstone Medical’s EVOLUTION lung-cancer program is in Phase 2, while its collaboration with the U.S. FDA focuses on methods for confident VOC identification in complex breath mixtures. These developments highlight the industry’s shift toward reproducibility, regulatory evidence and clinically actionable testing.
Segmentation Highlights
- By Type: Mass Spectrometry Technology Based Respiratory Detection; Gas Chromatography-Mass Spectrometry Based Respiratory Detection; Sensor Based Respiratory Detection.
- By Application: Lung Cancer Early Screening; Colorectal Cancer Detection; Liver Cancer Detection; Esophageal Cancer Detection; Others.
- By End User: Hospitals; Diagnostic Laboratories; Cancer Research Institutes; Academic Medical Centers.
- By Sample Type: Exhaled Breath; Bronchoalveolar Lavage; Sputum Analysis.
- Technology position: Mass spectrometry-based respiratory detection holds the leading technology position, while sensor-based systems represent a potential decentralized growth opportunity if clinical performance is validated.
- Application position: Lung cancer early screening is the leading application because respiratory sampling is particularly aligned with lung-cancer screening and clinical-development pathways.
- Sample type: Exhaled breath represents the core non-invasive opportunity and is positioned to capture incremental growth as repeat and decentralized testing models develop.
Regional Outlook
- North America remained the largest regional market in 2025, supported by cancer-screening infrastructure, clinical-trial activity, diagnostic investment and regulatory capabilities.
- United States: The country has a substantial addressable screening population, with NCI SEER estimating 229,410 new lung and bronchus cancer cases in 2026.
- Europe: The region has a strong translational-research base for breath biomarkers, particularly across the United Kingdom, Germany and Nordic markets.
- Asia-Pacific: The region offers substantial long-term growth potential as cancer burden and diagnostic capacity expand across major markets including China, Japan, South Korea and Australia.
- Latin America: Adoption opportunities are linked to improving access to non-invasive diagnostic assessment and cost-optimized testing models.
- Middle East & Africa: Adoption remains selective, with Israel and Gulf markets representing areas of advanced diagnostic and technology investment.
Download the free sample report: Available through the report page.
Why This Market Matters
Cancer respiratory biopsy is developing around a clear clinical opportunity: providing less-invasive approaches for cancer detection, screening support and diagnostic triage. Breath-based testing can potentially enable repeated sampling without needles or invasive instrumentation, creating opportunities for longitudinal monitoring and decentralized collection.
The commercial opportunity extends beyond conventional breath analysis. At-home collection, portable sensor systems, exogenous VOC probes and multi-cancer testing could broaden the addressable testing population. However, routine adoption will depend on prospective clinical evidence demonstrating that respiratory testing can improve diagnostic decisions, screening participation or downstream efficiency relative to established pathways.
Competitive Landscape
- Owlstone Medical — Develops an integrated breath-biopsy platform involving standardized breath collection, VOC analysis, EVOC probe technology and lung-cancer clinical development.
- Breath Diagnostics — Participates in the emerging respiratory biopsy and breath-diagnostics landscape.
- Menssana Research — Develops breath-analysis capabilities relevant to disease detection.
- Sensigent — Participates in sensor-based breath-analysis technology.
- Syft Technologies — Provides analytical capabilities relevant to high-sensitivity VOC measurement and respiratory biomarker analysis.
View the full report: https://www.intelmarketresearch.com/cancer-respiratory-biopsy-market-3188
FAQ
Q: What is the Cancer Respiratory Biopsy Market size and forecast?
A: The market was valued at USD 410 million in 2025, is estimated at USD 480 million in 2026 and is projected to reach USD 1.70 billion by 2034 at a 17.1% CAGR during 2026–2034.
Q: Which region leads the Cancer Respiratory Biopsy Market?
A: North America remained the largest regional market in 2025.
Q: Which technology and application are central to market development?
A: Mass spectrometry-based respiratory detection holds the leading technology position, while lung cancer early screening remains the leading application.
What Does the Full Report Cover?
The full study provides a detailed view of the emerging cancer respiratory biopsy ecosystem beyond headline market size and CAGR. It examines the market by technology type, cancer application, end user and respiratory sample type, alongside regional and selected country-level analysis. The report evaluates market dynamics including cancer burden, screening pathways, VOC standardization, clinical validation, capital requirements and regulatory considerations. It also examines competitive positioning, analytical differentiation, clinical-development programs and partnership activity. Technology assessment covers mass spectrometry, GC-MS, sensor-based detection, breath collection and exogenous VOC probe systems. The study further addresses prospective clinical utility, emerging multi-cancer pathways and opportunities associated with decentralized and at-home testing.
View the complete report: https://www.intelmarketresearch.com/cancer-respiratory-biopsy-market-3188
Download the free sample: Available through the report page.
Related Reports
- Pharmacogenomics (PGx) Market
- ArF Excimer Lasers Market
- Cardio-Renal-Metabolic Therapeutics Market
About Intel Market Research
Intel Market Research provides quantified market research and strategic intelligence covering emerging industries and technology-driven markets. Its research combines market sizing, forecasting, competitive analysis, regional assessment and industry-focused insights to support business and strategic decision-making.
Contact Details
Website: www.intelmarketresearch.com
Asia-Pacific: +91 9169164321
